IP U.S. reverses stance, backs giving poorer countries access to COVID vaccine patents:
President Joe Biden in May threw his support behind waiving intellectual property rights
for COVID-19 vaccines – very much to the surprise of the biotech world.
European biotechs have been longly undervalued. In the wake of the COVID-19 pandemic, some of them took off. They will have to prove their value in a post-COVID era. However, Europe is there.
Hague Court of Appeal (CoA) sets Dutch approach to the doctrine equivalence reversing District Court, handing Eli Lilly another win in its pan-European battle over infringement of its pemetrexed patents and bringing it in line with approaches taken elsewhere in Europe like in Germany and in the UK.
Women make up half of the world’s population. Finally, pharma companies and invetors are now beginning to pay more attention to female diseases.
The COVID-19 pandemic is putting our health systems in Europe to the test. Capacity bottlenecks are becoming apparent, as are long-neglected investments in modern infrastructure. As the pandemic does not stop at national borders, cross-border healthcare solutions are more urgent than ever.
Medical Cannabis – Last year, the European Cannabis Association was launched as industry interest group, but than the novel coronavirus pandemic changed everything. European Biotechnology spoke with Rainer Krüger, one of the ECA founders, how the virus changed the schedule and strategy to establish a science-based regulation for medicinal cannabis.
The COVID-19 pandemic is having a devastating effect on global health and an unprecedented impact on the economy. As the world struggles with the challenges brought on by this pandemic, the threat of the next one is already looming in the form of AMR.
In September, Unilever announced a €1bn investment to improve the sustainability of its cleaning brands from the ground up. European Biotechnology spoke to Dr Neil Parry, R&D programme director of biotechnology and biosourcing at Unilever about the goals of Clean Future.
Abigail Herron from Aviva Investors describes why AMR is a blind spot for investors and which action is needed to change it.
SPCs offer up to five and a half years of additional protection after patent expiration for pharmaceuticals in order to compensate the patent holder’s inability to exploit their inventions while products undergo lengthy regulatory approvals.